59-05-032 Proceeding

207 Proceedings of the Princess Maha Chakri Sirindhorn Congress D. Mortality and survival analysis Table 4 Comparison between SLE patients with and with mortality Yes (n=99) No (n=592) P-value Male (%) 15 (15.2) 63 (10.6) 0.189 Ageatonset (y/0) 51.6 ± 20.0 39.0 ± 14.5 < 0.001* Ageatadmission (y/o) 46.5 ± 22.5 34.6 ± 14.5 < 0.001* SLEduration (yrs) Clinicalfeatures 7.1 ± 7.7 8.8 ± 6.9 0.026* Malar rash (%) 36 (38.7) 268 (46.1) 0.182 Discoidrash (%) 9 (9.7) 54 (9.3) 0.902 Photosensitivity (%) 4 (12.4) 86 (14.8) 0.006* Oralulcer (%) 18 (19.4) 153 (26.3) 0.153 Arthritis (%) Serositis(%) 41 (43.6) 66 (66.7) 318 (54.6) 184 (31.3) 0.047* < 0.001* Proteinuria (%) Cellularcast (%) 76 (76.8) 17 (17.2) 336 (57.1) 86 (14.7) < 0.001*0.516 Anemia (%) 40 (40.4) 166 (28.1) 0.014* Leukopenia (%) 68 (68.7) 296 (50.1) 0.001* Lymphopenia (%) 92 (92.9) 421 (71.2) < 0.001* Thrombocytopenia (%) 81 (81.8) 225 (38.1) < 0.001* Psychosis (%) 8 (8.1) 43 (7.3) 0.777 Seizure (%) 27 (27.3) 45 (7.6) < 0.001* C3 69.4 ± 30.0 68.3 ± 33.3 0.759 C4 Anti-dsDNA (+) (%) 13.8 ± 8.0 60 (60.6) 13.6 ± 9.8 428 (72.5) 0.850 0.016* Anti-dsDNA level 430.4 ± 641.2 445.8 ± 591.0 0.815 Anti-Sm (%) Anti-SSA (%) Anti-SSB (%) Anti-RNP (%) 26 (32.1) 42 (62.7) 18 (27.3) 33 (41.8) 186 (38.8) 273 (64.2) 131 (30.8) 213 (44.5) 0.248 0.806 0.559 0.655 aPL (%) 39 (44.8) 175 (34.5) 0.064 Comorbidity HTN (%) 49 (49.5) 172 (29.1) < 0.001* DM (%) 14 (14.1) 37 (6.3) 0.005* ESRD (%) 25 (25.3) 37 (6.3) < 0.001* CVA (%) 18 (18.2) 37 (6.3) < 0.001*